{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhu Y"],"funding":["Henan Province Health Young and Middle-Aged Discipline Leader Project","The Provincial and Ministry Co-constructed Key Projects of Henan Medical Science and Technology","ZHONGYUAN QIANREN JIHUA","Henan Medical Key Laboratory of Refractory lung cancer","Henan International Joint Laboratory of drug resisitance and reversal of targeted therapy for lung cancer","Henan Refractory Lung Cancer Drug Treatment Engineering Technology Research Center","Henan Province Health and Youth Subject Leader Training Project","the 51282 project Leading Talent of Henan Provincial Health Science and Technology Innovation Talents","Leading Talent Cultivation Project of Henan Health Science and Technology Innovation Talents","National Natural Science Foundation of China (NSFC)","Henan Province Young and Middle-aged Health Science and Technology Innovation Leading Talent Project","Huilan Charity Fund"],"pagination":["145"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12690969"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["30(1)"],"pubmed_abstract":["<h4>Background</h4>Lung cancer, primarily lung adenocarcinoma (LUAD), is the leading cause of cancer-related deaths worldwide. Despite extensive research, the mechanisms behind LUAD progression remain inadequately understood, underscoring the need for new biomarkers and therapeutic targets. Ribosomal proteins, traditionally associated with protein synthesis, are gaining recognition for their roles in tumorigenesis, though many functions remain unexplored.<h4>Methods</h4>This study utilized single-cell transcriptomic data and bioinformatics analyses to identify potential LUAD biomarkers. Selected biomarkers were validated using quantitative PCR (qPCR) and immunofluorescence on clinical samples. Functional roles were assessed through in vivo and in vitro assays, including migration, invasion"],"journal":["Cellular & molecular biology letters"],"pubmed_title":["Ribosomal protein RPL7A modulates lung adenocarcinoma progression via circRANBP17-UPF1-mediated SIRT6 degradation."],"pmcid":["PMC12690969"],"funding_grant_id":["[2020]60","SBGJ202401004","YXKC2020009","[2021]10","HL-HS2020-129","[2020]27","[2016]32","ZYQR201912118","HNSWJW-2022011","[2020]4","YXKC2022004","81872204"],"pubmed_authors":["Liu Y","Pan Y","Wang Q","Zhu Y","Zhang Z","Zhou S","Han J","Chen H","Sun Z"],"additional_accession":[]},"is_claimable":false,"name":"Ribosomal protein RPL7A modulates lung adenocarcinoma progression via circRANBP17-UPF1-mediated SIRT6 degradation.","description":"<h4>Background</h4>Lung cancer, primarily lung adenocarcinoma (LUAD), is the leading cause of cancer-related deaths worldwide. Despite extensive research, the mechanisms behind LUAD progression remain inadequately understood, underscoring the need for new biomarkers and therapeutic targets. Ribosomal proteins, traditionally associated with protein synthesis, are gaining recognition for their roles in tumorigenesis, though many functions remain unexplored.<h4>Methods</h4>This study utilized single-cell transcriptomic data and bioinformatics analyses to identify potential LUAD biomarkers. Selected biomarkers were validated using quantitative PCR (qPCR) and immunofluorescence on clinical samples. Functional roles were assessed through in vivo and in vitro assays, including migration, invasion","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-06T00:18:26.609Z","creation":"2026-05-23T03:14:06.434Z"},"accession":"S-EPMC12690969","cross_references":{"pubmed":["41372808"],"doi":["10.1186/s11658-025-00779-7"]}}